Last reviewed · How we verify
NCT01937377
GLORIA-AF Registry Program (Phase II/III)
trial in Stroke in 200 participants. Completed in 15 April 2019.
15 April 2019
Quick facts
| Lead sponsor | Boehringer Ingelheim |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 2 September 2013 |
| Primary completion | 15 April 2019 |
| Estimated completion | 15 April 2019 |
| Sites | 5 locations across Switzerland |
Conditions studied
- Stroke — all drugs for Stroke →
- Atrial Fibrillation — all drugs for Atrial Fibrillation →
Sponsor
Boehringer Ingelheim — full company profile →
Who can join
18 and older, any sex, with Stroke or Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. For administrative purposes the study is divided into three protocol numbers: 1160.129 for all non-EU (European Union) and non-EEA (European Economic Area) countries, 1160.136 for EU and EEA countries and 1160.171 for Switzerland. The total number of patients enrolled in three protocols is estimated to be 48,000 patients, and all these patients will be included in the data analysis for study 1160.129.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Evaluation of bleeding in patients receiving direct oral anticoagulants.
Hellenbart EL, Faulkenberg KD, Finks SW. · · 2017 · cited 64× · PMID 28860793 · DOI 10.2147/vhrm.s121661 -
Patterns of comorbidities in patients with atrial fibrillation and impact on management and long-term prognosis: an analysis from the Prospective Global GLORIA-AF Registry.
Romiti GF, Corica B, Mei DA, Bisson A, et al · · 2024 · cited 45× · PMID 38589864 · DOI 10.1186/s12916-024-03373-4 -
Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry.
Romiti GF, Corica B, Proietti M, Mei DA, et al · · 2023 · cited 32× · PMID 37753446 · DOI 10.1016/j.eclinm.2023.102039 -
Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.
Bayer V, Kotalczyk A, Kea B, Teutsch C, et al · · 2022 · cited 30× · PMID 35243870 · DOI 10.1161/jaha.121.023907 -
Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world.
Kozieł M, Teutsch C, Bayer V, Lu S, et al · · 2021 · cited 29× · PMID 34386125 · DOI 10.1002/joa3.12588 -
Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA-AF Registry.
Ding WY, Lane DA, Gupta D, Huisman MV, et al · · 2022 · cited 28× · PMID 35876418 · DOI 10.1161/jaha.122.026410 -
Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry.
Ding WY, Calvert P, Gupta D, Huisman MV, et al · · 2022 · cited 14× · PMID 35488127 · DOI 10.1007/s00392-022-02022-1 -
Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up.
Kozieł M, Mazurek M, Teutsch C, Diener HC, et al · · 2020 · cited 13× · PMID 32586056 · DOI 10.3390/jcm9061969
Verify or expand the search:
- PubMed search for NCT01937377
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stroke
Currently open trials in the same condition.
- NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
- NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
- NCT07356011 — Exoskeleton for Balance · NA · recruiting
- NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in · NA · recruiting
- NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting
Other Boehringer Ingelheim trials
Trials by the same sponsor.
- NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
- NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
- NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
- NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
- NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01937377 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
- Last refreshed: 15 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01937377.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing